Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAOA | P21397 | 7/20 | 0.49 |
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | UNG | P13051 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607567 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAOAMAOBUNGTRPA1 | |
| SCHEMBL27780984 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAOAMAOBUNGCYP2A6 | |
| SCHEMBL6852425 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAOAMAOBUNGCYP2A6 | |
| SCHEMBL9079801 | 0.80 | MAOA (0.50) | ALDH1A1MAOAMAOBUNGCYP2A6 | |
| Benzyl Bromide SCHEMBL30423789 | 0.80 | ALDH1A1 (0.64) | ALDH1A1MAOAMAOBUNGTRPA1 | |
| SCHEMBL31139357 | 0.80 | MAOB (0.74) | ALDH1A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL20233485 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAOAMAOBUNGCYP2A6 | |
| SCHEMBL13536780 | 0.79 | DRD1 (0.47) | ALDH1A1TRIM24TRIM33CA12CA1 | |
| SCHEMBL6406763 | 0.79 | ACHE (0.47) | ALDH1A1MAOAMAOBCYP2A6 | |
| SCHEMBL417837 | 0.78 | MAOA (0.58) | ALDH1A1MAOAMAOBUNGCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359494-A | Fluorescent probe capable of specifically recognizing lysine and preparation method thereof | 海南大学 | 2024-07-19 | — | — | CN | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250339406-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-11-06 | — | — | US | disclosed |
| EP-4612149-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-1994019352-A1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) | 1994-09-01 | — | — | WO | disclosed |
| US-5306728-A | Substituted amine derivatives having antihyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0548235-A1 | SYNTHETIC DRUG MOLECULES THAT MIMIC METALLOENZYMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-06-30 | — | — | EP | disclosed |
| US-5217966-A | Synthetic drug molecules that mimic metalloenzymes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-06-08 | — | — | US | disclosed |
| US-5202317-A | SYNTHETIC DRUG MOLECULES THAT MIMIC METALLOENZYMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-04-13 | — | — | US | disclosed |
| WO-1992005178-A1 | SYNTHETIC DRUG MOLECULES THAT MIMIC METALLOENZYMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-04-02 | — | — | WO | disclosed |
| EP-0448078-A2 | Substituted amine derivatives having anti-hyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
| US-4389410-A | Esters of monic acid A useful as antibacterial and antimycoplasmal agents | BEECHAM GROUP LIMITED (GB) | 1983-06-21 | — | — | US | disclosed |
| EP-0045150-A1 | Antibacterial compounds, processes for their preparation and composititions containing them | BEECHAM GROUP PLC (GB) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | ALDH1A1 999/4885MAOA 3706/4885MAOB 2808/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ALDH1A1 3227/4885MAOA 3267/4885MAOB 3343/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | ALDH1A1 3579/4885MAOA 2166/4885MAOB 2303/4885 |
| US-20250339406-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | NSD3, NSD2, NSD1 | ALDH1A1 3591/4885MAOA 4166/4885MAOB 3769/4885 |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER4, PTGER1, PTGER3 | ALDH1A1 2468/4885MAOA 2505/4885MAOB 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.